Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00645034 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin
A Phase 2 study of Benign Prostatic Hyperplasia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT00645034: Completed Phase 2 study of Benign Prostatic Hyperplasia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00645034 is a Phase 2 study of Benign Prostatic Hyperplasia that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 20 participants, below the 551-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00645034, a Phase 2 study of Benign Prostatic Hyperplasia, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
To investigate the effects of a single dose of sildenafil (100 mg) or placebo on blood pressure and pulse rate in subjects taking doxazosin for benign prostatic hyperplasia (BPH). To investigate the pharmacokinetics of doxazosin when co-administered with sildenafil 100 mg, and to investigate the safety and toleration of sildenafil 100 mg when co-administered with doxazosin.
Conditions Studied
Interventions
- DRUG placebo
- DRUG sildenafil
Study Locations (2)
California
- Pfizer Investigational Site - Laguna Woods
- Pfizer Investigational Site - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2002-11 |
| Est. Completion | 2003-07 |
| Phase | Phase 2 |
What the finished NCT00645034 record still lists
NCT00645034 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 551-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Benign Prostatic Hyperplasia appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00645034 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00645034 about?
NCT00645034 is a clinical study titled "A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin". To investigate the effects of a single dose of sildenafil (100 mg) or placebo on blood pressure and pulse rate in subjects taking doxazosin for benign prostatic hyperplasia (BPH). To investigate the pharmacokinetics of doxazosin when co-administered with sildenafil 100 mg, and to investigate the saf...
What is the current status of trial NCT00645034?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2002-11. Estimated completion is 2003-07.
What conditions does trial NCT00645034 study?
This clinical trial studies the following conditions: Benign Prostatic Hyperplasia.
What interventions are being tested in trial NCT00645034?
The interventions under investigation include: placebo (DRUG), sildenafil (DRUG).
Who is sponsoring clinical trial NCT00645034?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00645034 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Prostatic Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00645034's enrollment target sits among peer trials
20 28th of 29 higher than 2 of 29 other Benign Prostatic Hyperplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Benign Prostatic Hyperplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
COMPLETED · Phase 2
-
Botulinum Toxin Injection for the Management of BPH
COMPLETED · Phase 2
-
Customized TULSA-PRO Ablation Registry
RECRUITING
-
OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH
RECRUITING
-
Ambulatory Long Length URodynamics Evaluation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia